timolol has been researched along with imiquimod in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Antaya, RJ; Craiglow, BG | 1 |
| Chen, H; Hu, X; Jin, Y; Lin, X; Ma, G; Qiu, Y; Yang, J | 1 |
| Berrios, R; Hutchens, KA; Millsop, JW; Trinh, N; Tung, R; Winterfield, L | 1 |
| Hu, L; Huang, HZ; Li, W; Li, X; Lin, XX | 1 |
| Fabi, SG; Zaleski-Larsen, LA | 1 |
| Lipner, SR | 1 |
3 review(s) available for timolol and imiquimod
| Article | Year |
|---|---|
Management of infantile hemangiomas : current and potential pharmacotherapeutic approaches.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aminoquinolines; Hemangioma; Humans; Imiquimod; Infant; Off-Label Use; Propranolol; Skin Neoplasms; Timolol | 2013 |
Laser-Assisted Drug Delivery.
Topics: Administration, Cutaneous; Adrenergic beta-Antagonists; Aminolevulinic Acid; Aminoquinolines; Analgesics; Antibodies; Antineoplastic Agents; Ascorbic Acid; Cyclopropanes; Dermatologic Agents; Drug Delivery Systems; Fluorouracil; Humans; Imiquimod; Immunotherapy; Laser Therapy; Methotrexate; Minoxidil; Permeability; Photosensitizing Agents; Polyesters; RNA, Small Interfering; Skin; Timolol; Vaccines | 2016 |
Topical Adjuncts to Pulsed Dye Laser for Treatment of Port Wine Stains: Review of the Literature.
Topics: Administration, Cutaneous; Aminoquinolines; Clinical Trials as Topic; Combined Modality Therapy; Dermatologic Agents; Humans; Imiquimod; Lasers, Dye; Port-Wine Stain; Randomized Controlled Trials as Topic; Sirolimus; Timolol; Treatment Outcome | 2018 |
1 trial(s) available for timolol and imiquimod
| Article | Year |
|---|---|
Open-label nonrandomized left-right comparison of imiquimod 5% ointment and timolol maleate 0.5% eye drops in the treatment of proliferating superficial infantile hemangioma.
Topics: Aminoquinolines; Antineoplastic Agents; Extremities; Facial Neoplasms; Female; Hemangioma, Capillary; Humans; Imiquimod; Infant; Male; Neoplastic Syndromes, Hereditary; Non-Randomized Controlled Trials as Topic; Ointments; Ophthalmic Solutions; Skin Neoplasms; Timolol; Torso | 2015 |
4 other study(ies) available for timolol and imiquimod
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Imiquimod 5% cream versus timolol 0.5% ophthalmic solution for treating superficial proliferating infantile haemangiomas: a retrospective study.
Topics: Administration, Topical; Adrenergic beta-Antagonists; Aminoquinolines; Antineoplastic Agents; Female; Hemangioma; Humans; Imiquimod; Infant; Male; Retrospective Studies; Skin Neoplasms; Timolol | 2013 |
Resolution of recalcitrant pyogenic granuloma with laser, corticosteroid, and timolol therapy.
Topics: Administration, Cutaneous; Adrenal Cortex Hormones; Adult; Aminoquinolines; Anti-Bacterial Agents; Biopsy; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Therapy, Combination; Granuloma, Pyogenic; Humans; Imiquimod; Laser Therapy; Lasers, Dye; Lasers, Solid-State; Male; Recurrence; Scalp Dermatoses; Timolol; Triamcinolone Acetonide | 2014 |
Patient Perspectives: What is a pyogenic granuloma?
Topics: Adrenergic beta-Antagonists; Aminoquinolines; Biopsy; Granuloma, Pyogenic; Humans; Imiquimod; Interferon Inducers; Laser Therapy; Timolol | 2018 |